Slides on Key Decisions in HIV Care: Considering Tenofovir Alafenamide in Pregnancy

Learn the latest data about whether to use tenofovir alafenamide during pregnancy.
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Format: Microsoft PowerPoint (.ppt)
File Size: 351 KB
Released: September 24, 2021

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Leticia M. Pérez Saleme, MD Released: May 19, 2022

Preguntas respondidas por expertas de Clinical Care Options (CCO) sobre las mejores prácticas para cambiar el TAR en pacientes suprimidos en México.

person default Alicia Piñeirúa Menéndez, MD, MPH Leticia M. Pérez Saleme, MD Released: May 17, 2022

Expert HIV faculty analyze new data from CROI 2022, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Jason E. Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRN Jasjit Gill, BSPharm, PharmD
Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 10, 2022 Expired: May 9, 2023

Expert selections of data for state-of-the-art switch strategies in virologically suppressed patients.

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Paul E. Sax, MD
Released: May 6, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings